The objective of this study is to evaluate the presence of TL1A and the levels of CD40L in neurosarcoidosis patients and assess their relationship to disease activity.

Neurosarcoidosis is a rare inflammatory disease that lacks reliable biomarkers to monitor disease activity. Soluble markers such as TL1A (TNSF15) and CD40L, both involved in immune regulation, are of interest for their potential roles in inflammatory disease activity. This study evaluates the association of TL1A and CD40L levels with active versus inactive neurosarcoidosis.

Serum samples from neurosarcoidosis patients were analyzed for TL1A and CD40L concentrations. Patients were classified by disease activity (active vs. inactive) at the time of sampling based on MRI findings (enhancing vs. non-enhancing lesions). TL1A concentrations were categorized as detectable or undetectable. CD40L levels were compared between active and inactive groups using a t-test.

Of the 24 neurosarcoidosis patients, only 6 had detectable TL1A levels. However, all patients with detectable TL1A levels had active disease. For CD40L, the mean concentration in active patients (n=16) was 9.90 pg/ml compared to 8.96 pg/ml in inactive patients (n=8) with p-value of 0.60 indicating no significant difference in CD40L levels between the two groups (95% Cl: -2.80 to 4.69).

This study offers valuable insight into distinguishing active neurosarcoidosis particularly through the detection of TL1A. Although TL1A showed low detectabiliy which limited its utility as a standalone biomarker, its presence in a subset of patients with active disease suggests potential relevance and warrants further investigation using more sensitive techniques. To continue, CD40L levels did not differ significantly between active and inactive neurosarcoidosis patients. This indicates it may not serve as a reliable biomarker for disease activity on its own. Future studies with larger sample sizes may help clarify the roles of these biomarkers in neurosarcoidosis.